Spyglass Ophthalmics Stock

www.spyglasspharma.comHealthcare / Medical DevicesFounded: 2019

SpyGlass Ophthalmics, founded in 2019, is developer of ophthalmic devices and drug delivery platform intended to improve vision and eye care. Spyglass's devices seek to address unmet needs in cataract, lens replacement, surgery, and other chronic ophthalmic diseases, with the aim of enabling patients to get quality eye treatment at an affordable cost. SpyGlass Pharma is headquartered in Aliso Viejo, California.

Register for Details

For more details on financing and valuation for Spyglass Ophthalmics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Spyglass Ophthalmics.

Register Today


Management Team

Malik Kahook MD
Co-Founder, President & Executive Chairman
James Dennewill
Chief Operating Officer
Glenn Sussman
Co-Founder & Chief Technology Officer
Patrick Mooney
Chief Executive Officer, Vice President of Research and Development & TalentWell Marketing Specialist

Board Members

Ali Behbahani MD
New Enterprise Associates

Other companies like Spyglass Ophthalmics in the Medical Devices sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

SpyGlass Pharma Closes $90M Series C
SpyGlass Pharma, an Aliso Viejo, CA-based ophthalmic therapeutics company, raised $90M in Series C funding. The round was led by RA Capital Management alongside existing investors New Enterprise Associates and Vensana Capital, as well as new investors Samsara BioCapital and Vertex Ventures HC.
Updated on: Oct 3, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.